Chloroquine/remdesivir (Vyripharm Biopharmaceuticals)

N/A

Report date: 2024/04/29 17:39:35

Base Information

Drug NameChloroquine/remdesivir (Vyripharm Biopharmaceuticals)
Drug Alias NameVYR-2020
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCannabinoid CB1 receptor antagonistsImmunosuppressantsDNA intercalators +[8] 
TargetsHemozoinDNACannabinoid CB1 receptor +[6] 
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Coronavirus InfectionsSevere Acute Respiratory Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes Chloroquine hydrochlorideRemdesivir
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesVyripharm Biopharmaceuticals LLC
China Registration ClassN/A

Develop Information

Active CompaniesVyripharm Biopharmaceuticals LLC
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Coronavirus InfectionsSevere Acute Respiratory Syndrome
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A